Last reviewed · How we verify

NCT06891586

Blood Phoenixin-14 Levels and Echocardiographic Findings in Infants of Diabetic Mothers

Recruiting now NA Last updated 27 March 2026
What this trial tests

NA trial testing echocardiographic evaluation and blood phoenixin-14 level in Newborn Morbidity in 84 participants. Currently enrolling.

Timeline
1 September 2024
Primary endpoint
1 October 2025
1 October 2026

Quick facts

Lead sponsorKonya City Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment84
Start date1 September 2024
Primary completion1 October 2025
Estimated completion1 October 2026
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Konya City Hospital

Who can join

Adults 1 Day to 5 Days, any sex, with Newborn Morbidity or Newborn Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the investigators hypothesize that echocardiographic pathologies observed in infants of diabetic mothers are associated with elevated serum phoenixin-14 levels.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Newborn Morbidity

Currently open trials in the same condition.

Other Konya City Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06891586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing